3: Disappointing Data. Cosentyx Doesn’t Deliver in Giant Cell Arteritis

Novartis’ blockbuster Cosentyx has hit a wall. In this episode of The Biotech Brief, we unpack the Phase 3 GCAptAIN trial results, where Cosentyx failed to show benefit for patients with giant cell arteritis. We explore what GCA is, why this label expansion mattered, and how the drug—once seen as a contender in this space—fell short. Plus, we look at the commercial implications, the competitive IL-6 landscape, and what this means for the future of Cosentyx and Novartis’ inflammatory disease pipeline.